Lupin launches Prucalopride Tablets in United States
Prucalopride Tablets, 1 mg, and 2 mg had estimated annual sales of $184 million in the U.S.
Lupin has launched Prucalopride Tablets, 1 mg, and 2 mg, in the United States (U.S.), following the recent approval of its Abbreviated New Drug Application (ANDA) from United States Food and Drug Administration (USFDA).
Prucalopride Tablets are bioequivalent to Motegrity tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc., and indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride Tablets, 1 mg, and 2 mg (RLD Motegrity) had estimated annual sales of $184 million in the U.S. (IQVIA MAT April 2025).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
